Role of Molecular Advances in the Classification and Prognosis of MDS
This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Compare and contrast the current and developing complementary diagnostic assays and molecular analyses and how these tests can be used to advance the classification and prognostication of MDS
Peter L. Greenberg, MD
Stanford Cancer Institute
- 0.50 Participation
- 0.57 Nurse
- 0.50 Pharmacist
- 0.50 Physician